Juan Luis Ontiveros, MD

En el laboratorio estamos celebrando que la Dra. Florencia Rosetti @florerosetti y su equipo obtuvieron el premio CANIFARMA 2025 por el estudio del factor de transcripción Helios y su papel en la respuesta inmune antitumoral. Un orgullo para el @autoinmunilab y el @incmnszmx!

Fresh from the oven!

🚨 New Study Alert! @nihardesai89 @Haemophage @IvanPasic Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromes—a rare and challenging group of hematologic neoplasms. 🧵👇

📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not. More news: lymphoblastic-hub.com #allsm #leusm #MedNews #MedEd

📢 Body composition in adult ALL 📊 In our study published at @ESPENorg, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections. clinicalnutritionespen.com/article/S2405-… @RobertaDemiche3 @FernandoGLMD @analymorac @JessicaZaS

@drmacerecedor @CharlatanesMed Justo te lo iba a mandar para ver tu experta opinión. A mí me gusta el chismecito jajaja

@CharlatanesMed Y solo es la punta del iceberg de ese fulano

Buen día, sobrinos. Les traje un caso muy bueno. Se llama Etelberto Cruz. Dice ser cirujano oncólogo. Como buen #charlatan se anuncia con bombo y platillo pero, como es habitual, no cuenta con cédula de cirugía y mucho menos de cirugía oncológica. Esto es en #Hidalgo

@RaulAldesleukin Me sorprende que no lo haya hecho, doctor

Que es esté urge de todo mundo de hacerse un Instagram tipo Dr/Dra tal.. R0 de ….

🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉 Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario. 🔗 docs.google.com/forms/d/e/1FAI… Tu aporte será clave para mejorar la atención de LLA en la región.

@SergioRdzRdz @Haemophage @nihardesai89 @IvanPasic @CIBMTR @ASTCT I'm the MOST proud of my friend

Ready for #Tandem25. Missing @Haemophage @nihardesai89 @IvanPasic @CIBMTR @ASTCT

So proud of being part of this project.

@dgomezalmaguer Ya tendrán los resultados in vitro?

Esperando a que Cofepris apruebe nuestro estudio clínico sobre CAR-T cells. Tenemos ya la capacidad para desarrollarlas, de hecho ya lo hemos hecho y solo nos falta aplicarlo en pacientes.

1/ Rituximab in ALL: What we know For Ph-neg B-ALL, rituximab has shown clear benefits: 🩺 Improved EFS (in trials like GRAALL-2005) 🩺 Enhanced outcomes, esp with ≥8 doses But for Ph-pos B-ALL evidence is lacking, as most trials exclude these patients

Today we had the visit of Doctor Rahul Purwar and Dr Hasmukh Jain from the TATA Institute and immunoACT who shared their experience of “Make-in-India” first CART therapy. We hope that this could become a reality for Mexican patients @incmnszmx @RobertaDemiche3 @autoinmunilab

Come visit this great abstract session coordinated by my mentor @RobertaDemiche3. Very interesting topics for improving our ALL outcomes. #ASH24 @ContactoAmeh @ASH_hematology

@AlcazerVincent @RobertaDemiche3 @ContactoAmeh @ASH_hematology Thank you! It's done.

@JuanLmd @RobertaDemiche3 @ContactoAmeh @ASH_hematology Thank you for your feedback! I cannot dm you for the moment (have to either follow me or enable the option for receiving dm from anyone)

So proud of my mentor @RobertaDemiche3 speaking about our country's limitations for leukemia diagnosis. The first step for improvement is knowing our problems. #ASH24 @ContactoAmeh @ASH_hematology

@AlcazerVincent @RobertaDemiche3 @ContactoAmeh @ASH_hematology Sure! We're very interested in improving our access to rapid diagnosis! Please, DM me your email for contacting you. It would be great if we could collaborate.

@JuanLmd @RobertaDemiche3 @ContactoAmeh @ASH_hematology We develloped a tool for leukemia diagnosis using only blood count and I would be highly interested to evaluate its benefit in a Mexican population. Please do not hesitate to contact me if you are interested in a collaboration on the topic! thelancet.com/journals/landi…

There's a lot to learn from pediatric hematologists about treating AYAs. Great abstracts that encourage adapted treatments in our patients. #ASH24

@IsRubens @SergioRdzRdz @fcojavier_gr @NunezAtahualpa @ASH_hematology @AML_Hub Interesting proposal, but I think that myelotoxicity is considerable. I'd rather prefer lower intensity regimens and wait for transplantation.

#AML :7+3 plus Venetoclax, I don’t know men, too much toxicity and what about in transplant candidates. What do you think? @SergioRdzRdz @JuanLmd @fcojavier_gr @NunezAtahualpa #ASH24 @ASH_hematology @AML_Hub

@faustor @ASH_hematology @RobertaDemiche3 El mejoooor!!

Got great news to start #ASH24 that I got accepted into @ASH_hematology Advanced CRTI-LA. See you next year in Punta del Este 🇺🇾 thanks to my mentor @RobertaDemiche3! 🫰🏻🩸